Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53-specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing study

8 Apr 2024

Abstract excerpt

Abstract Background TP53 mutations and homologous recombination deficiency (HRD) occur frequently in breast cancer. However, the characteristics of TP53 pathogenic mutations in breast cancer patients with/without HRD are not clear. Methods Clinical next-generation sequencing (NGS) of both tumor and paired blood DNA from 119 breast cancer patients (BRCA-119 cohort) was performed with a 520-gene panel. Mutations,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38745917
DOI: 10.1093/pcmedi/pbae009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53-specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing studyPMID 38745917Read ↗

A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.Semantic proximity Read ↗

The utility of homologous recombination deficiency biomarkers across cancer typesSemantic proximity Read ↗

Validation of Genomic and Transcriptomic Models of Homologous Recombination Deficiency in a Real-World Pan-Cancer CohortSemantic proximity Read ↗

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer TypesSemantic proximity Read ↗

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.Semantic proximity Read ↗

Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.Semantic proximity Read ↗

Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohortSemantic proximity Read ↗

Somatic mutations in four novel genes contribute to homologous recombination deficiency in breast cancer: a real-world clinical tumor sequencing study.Semantic proximity Read ↗

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast CancerSemantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Genomic Determinants of Homologous Recombination Deficiency across Human CancersSemantic proximity Read ↗

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.